A Current Review of Targeted Therapeutics for Ovarian Cancer

Table 2

PDGF-targeted therapies in ovarian cancer.

clinical trial.gov ID	Therapeutic regimen	Study PI
NCT00913835	Doxil ± IMC 3G3 in platinum refractory or resistant EOC	W. McGuire
NCT00768144	Sunitinib in refractory/recurrent ovarian, fallopian tube, or peritoneal cancer	S. Campos
NCT00437372	Sunitinib and radiation therapy	A . Dicker
NCT00792545	Dasatinib + bevacizumab in surgically metastatic, or unresectable solid tumors	E. Kohn
NCT00672295	Dasatinib + paclitaxel + carboplatin in ovarian, fallopian tube, and peritoneal cancer	A. Secord
NCT00436215	Sorafenib + bevacizumab in recurrent/refractory ovarian, fallopian tube, or peritoneal cancer	E. Kohn
NCT00526799	Sorafenib + topotecan in platinum resistant EOC	D. Matei
NCT00390611	Paclitaxel + carboplatin ± sorafenib for first-line therapy for EOC	J. Hainsworth
NCT00096200,	Sorafenib + paclitaxel + carboplatin in recurrent platinum-sensitive ovarian, fallopian tube, or peritoneal cancer	V. von Gruenigan
NCT00510653	Gleevac study for patients with ovarian cancer	D. Gershenson
NCT00840450	Gleevac and paclitaxel with recurrent mullerian cancers	F. Muggia